期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2型糖尿病治疗新药剂利拉利汀的临床疗效观察 被引量：5

Analysis of the Clinical Application in the Treatment of Type 2 Diabetes of New Agentia Linagliptin
下载PDF
导出
摘要 目的探讨新药剂利拉利汀在2型糖尿病治疗中的应用效果。方法选取我院收治的2型糖尿病患者60例,分为对照组和观察组,每组患者30例,比较两组患者治疗的总有效率。结果经过治疗后,对照组患者治疗的总有效率为70%;观察组患者治疗的总有效率为96.67%,观察组患者的治疗效果优于对照组。结论新药剂利拉利汀应用中在2型糖尿病的治疗中具有良好的效果。 Objective To investigate the effect of new agentia linagliptin application in type 2 diabetes mellitus patients.MethodsA total of 60 type 2 diabetic patients in our hospital were divided into control group and observation group, 30 cases in each group of patients, a total efifciency were compared between the two groups of treatment.Results After treatment, the patients in the control group the total effective rate of treatment was 70%, the patients in the observation group were treated with a total effective rate of 96.67%, patients in the observation group treatment effect is better than that of control group.Conclusion The new agentia linagliptin application has good results in the treatment of type 2 diabetes.
作者 张天英 李洪影
机构地区 佳木斯大学附属第一医院药剂科
出处 《继续医学教育》 2015年第8期130-131,共2页 Continuing Medical Education
关键词 新药剂 利拉利汀 2型糖尿病 New agentia Linagliptin Type 2 diabetes
分类号 R977.15 [医药卫生—药品]
  • 相关文献

参考文献5

二级参考文献51

  • 1McIntosh CH, Demuth HU,Kim SJ, et ^/.Applications of dipeptidyl peptidase R^ inhibitors in diabetes mellitus[J]. IntJBiochem CellBioh2006,38(5-6) :860.
  • 2Thomas L,Eckhardt M, LangkopfE,e/al. (R)-8-(3-ami-no-piperidin-1 -yl) -7-but-2 -ynyl-3-methyl-1 - (4-methyl-qu-inazolin-2-ylmethyl) -3, 7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors [J]. JPharmacolExp Ther,2008,325(1) : 175.
  • 3Eckhardt M, Langkopf E, MarkM, et al. 8-(3-(R)-ami-nopiperidin-1 -yl) -7-but-2-ynyl-3-methyl-1 - (4-methyl-qu-inazolin-2-ylmethyl) -3, 7-dihydropxmne-2, 6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes[J]. JMed Chem, 2007,50(26) : 6 450.
  • 4Fuchs H,Tillement JP, Urien S,et al. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans[J]. J Pharm Pharmacol, 2009,61 (1) : 55.
  • 5Fuchs H, Binder R, Greischel A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats[J]. Biopharm Drug Dispos, 2009,30(5):229.
  • 6Eckhardt M, Hauel N,Himmelsbach F,e/ aL 3’ 5-Dihy-dro-imidazo[4, 5-d]pyridazin -4-ones : a class of potent DPP-4 inhibitors[J]. Bioorg Med Chem Lett, 2008, 18(11):3 158-China Pharmacy 2012Vol. 23 No. 34 . 3243 .
  • 7Blech S ’ Ludwig'Schwellinger E ’ Grafe-Mody EU, et al. The metabolism and disposition of the oral dipeptidyl pep-tidase-4 inhibitor, Iinagliptin, in humans [J]. Drug Metab Z)/5po5,2010,38(4):667.
  • 8Graefe MU, Friedrich C, Port A, et al. Linagliptin, a novel DPPA inhibitor: no need for dose adjustment in patients with renal impairment[C]. Poster 822-P, European Association for the Study of Diabetes Annual Meeting, 20-24 September 2010, Stockholm, Sweden.
  • 9Del Prato S, Bamett AH, Huisman H, et al. Effect of Iina-gliptin monotherapy on glycaemic control and markers of p-cell function in patients with inadequately controlled type 2 diabetes : a randomized controlled trial[J]. Diabetes Obes Metab,20ll, 13(3): 258.
  • 10Forst T, Uhlig-Laske B, Ring A, et aL Linagliptin (BI 1356) , a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes[J]. Diabet Afec/,2010,27(12);1 409.

共引文献18

同被引文献12

引证文献5

二级引证文献5

继续医学教育
2015年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部